Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand

Fennec Pharmaceuticals

14/05/2026 11:41

Overview

US specialty pharma's Q1 product sales rose 73% yr/yr on higher PEDMARK adoption

Company posted net income of $201,000, reversing a loss a year ago

Growth driven by expanded field sales and increased demand for PEDMARK

Outlook

Company expects to deliver sustained growth throughout 2026

Company anticipates cash and projected PEDMARK revenue will fund operations under current plan

Company sees growing clinical interest in PEDMARK across new patient populations

Result Drivers

PEDMARK ADOPTION - Co said higher Q1 sales were driven by increased adoption and deeper utilization of PEDMARK across both new and existing accounts, including in the AYA population

FIELD SALES EXPANSION - Strategic expansion of field sales force supported execution and contributed to record PEDMARK demand, per management

PATIENT SERVICES PROGRAM - Operational improvements in Fennec HEARS program led to more patients entering the funnel and improved patient experience, supporting PEDMARK utilization

Company press release: ID:nGNXbFC88G

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 PEDMARK Product Sales
$15.11 mln
Q1 Net Income
$201,000
Q1 Basic EPS
$0.01
Q1 Operating Expenses
$15.23 mln
Q1 Operating Income
-$119,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $15.50, about 129% above its May 13 closing price of $6.77

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)